Copyright Reports & Markets. All rights reserved.

Global Secondary Hyperparathyroidism Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Surgery
      • 1.4.3 Drugs
      • 1.4.4 Vitamin D
      • 1.4.5 Calcimimetics
      • 1.4.6 Phosphate Binders
    • 1.5 Market by Application
      • 1.5.1 Global Secondary Hyperparathyroidism Treatment Market Share by Application (2014-2025)
      • 1.5.2 Hospital Pharmacies
      • 1.5.3 Retail Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Secondary Hyperparathyroidism Treatment Market Size
    • 2.2 Secondary Hyperparathyroidism Treatment Growth Trends by Regions
      • 2.2.1 Secondary Hyperparathyroidism Treatment Market Size by Regions (2014-2025)
      • 2.2.2 Secondary Hyperparathyroidism Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Secondary Hyperparathyroidism Treatment Market Size by Manufacturers
      • 3.1.1 Global Secondary Hyperparathyroidism Treatment Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
    • 3.3 Key Players Secondary Hyperparathyroidism Treatment Product/Solution/Service
    • 3.4 Date of Enter into Secondary Hyperparathyroidism Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Secondary Hyperparathyroidism Treatment Market Size by Type (2014-2019)
    • 4.2 Global Secondary Hyperparathyroidism Treatment Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 5.2 Secondary Hyperparathyroidism Treatment Key Players in United States
    • 5.3 United States Secondary Hyperparathyroidism Treatment Market Size by Type
    • 5.4 United States Secondary Hyperparathyroidism Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 6.2 Secondary Hyperparathyroidism Treatment Key Players in Europe
    • 6.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Type
    • 6.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Application

    7 China

    • 7.1 China Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 7.2 Secondary Hyperparathyroidism Treatment Key Players in China
    • 7.3 China Secondary Hyperparathyroidism Treatment Market Size by Type
    • 7.4 China Secondary Hyperparathyroidism Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 8.2 Secondary Hyperparathyroidism Treatment Key Players in Japan
    • 8.3 Japan Secondary Hyperparathyroidism Treatment Market Size by Type
    • 8.4 Japan Secondary Hyperparathyroidism Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 9.2 Secondary Hyperparathyroidism Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Type
    • 9.4 Southeast Asia Secondary Hyperparathyroidism Treatment Market Size by Application

    10 India

    • 10.1 India Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 10.2 Secondary Hyperparathyroidism Treatment Key Players in India
    • 10.3 India Secondary Hyperparathyroidism Treatment Market Size by Type
    • 10.4 India Secondary Hyperparathyroidism Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Secondary Hyperparathyroidism Treatment Market Size (2014-2019)
    • 11.2 Secondary Hyperparathyroidism Treatment Key Players in Central & South America
    • 11.3 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Type
    • 11.4 Central & South America Secondary Hyperparathyroidism Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Amgen
      • 12.1.1 Amgen Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.1.5 Amgen Recent Development
    • 12.2 OPKO Health
      • 12.2.1 OPKO Health Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.2.5 OPKO Health Recent Development
    • 12.3 AbbVie
      • 12.3.1 AbbVie Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.3.5 AbbVie Recent Development
    • 12.4 Astellas Pharma
      • 12.4.1 Astellas Pharma Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.4.5 Astellas Pharma Recent Development
    • 12.5 Roche
      • 12.5.1 Roche Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.5.5 Roche Recent Development
    • 12.6 KAI Pharmaceuticals
      • 12.6.1 KAI Pharmaceuticals Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.6.5 KAI Pharmaceuticals Recent Development
    • 12.7 Kyowa Hakko Kirin
      • 12.7.1 Kyowa Hakko Kirin Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.7.5 Kyowa Hakko Kirin Recent Development
    • 12.8 Leo Pharma
      • 12.8.1 Leo Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.8.5 Leo Pharma Recent Development
    • 12.9 Shire
      • 12.9.1 Shire Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.9.4 Shire Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.9.5 Shire Recent Development
    • 12.10 Sanofi
      • 12.10.1 Sanofi Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Secondary Hyperparathyroidism Treatment Introduction
      • 12.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2014-2019)
      • 12.10.5 Sanofi Recent Development
    • 12.11 Deltanoid Pharmaceuticals

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
      In the treatment of secondary hyperparathyroidism due to chronic kidney disease on dialysis calcimimetics do not appear to affect the risk of early death. It does decrease the need for a parathyroidectomy but caused more issues with low blood calcium levels and vomiting.
      In 2018, the global Secondary Hyperparathyroidism Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.

      The key players covered in this study
      Amgen
      OPKO Health
      AbbVie
      Astellas Pharma
      Roche
      KAI Pharmaceuticals
      Kyowa Hakko Kirin
      Leo Pharma
      Shire
      Sanofi
      Deltanoid Pharmaceuticals

      Market segment by Type, the product can be split into
      Surgery
      Drugs
      Vitamin D
      Calcimimetics
      Phosphate Binders

      Market segment by Application, split into
      Hospital Pharmacies
      Retail Pharmacies

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Secondary Hyperparathyroidism Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Secondary Hyperparathyroidism Treatment development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Secondary Hyperparathyroidism Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now